These innovative agents represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://matteohlez709546.shoutmyblog.com/37989962/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide